COMPANY PROFILE

More

PRECISION MEDICINE ON EARLY, ACCURATE AND INFORMATIVE DIAGNOSES

Singlera Genomics is committed to the application of next generation sequencing to diagnose genetic diseases and disorders. Singlera Genomics develops non-invasive genetic tests using proprietary technologies including single cell sequencing, DNA methylation and machine learning. Singlera Genomics products address the continuing needs for cancer diagnosis, personalized cancer treatment, prenatal diagnosis, and pre-implantation genetic screening. Additionally, Singlera Genomics provides customized next generation sequencing services to pharmaceutical companies and medical research institutions. It has operation centers in the United States and China.

Singlera Genomics,

Inc. was founded

July 2014

July 2014

Singlera Genomics, Inc. was founded in San Diego, California, US and raised 50 million RMB from angel investors.

January 2015

Singlera Genomics

Shanghai was

registered in China

January 2015

Singlera Genomics Shanghai was registered and established as the China headquarters and Research and Development center in Shanghai, CN.

First product

to market

August 2015

August 2015

Singlera Genomics Shanghai launched a clinical test to detect mutations on solid tumor tissues.

October 2015

Signed

collaborative

agreement with

Xiangya Medical

Laboratory

October 2015

Singlera Genomics Shanghai signed a strategic collaborative agreement with the Xiangya Medical Laboratory of Central South University (Changsha, Hunan, CN) to provide a high-throughput genetic testing service of cancer mutations in a large collection of clinical samples.

Signed agreement

with Yale University

December 2015

December 2015

Singlera Genomics, Inc. signed agreement with Yale University (New Haven, Connecticut, US) for a study to test new-generation non-invasive prenatal testing techniques on clinical samples.

March 2016

Signed partnership

agreement with

Genor Biopharma

March 2016

Singlera Genomics Shanghai signed a partnership agreement with Genor Biopharma Co. Ltd. to jointly develop immunotherapy related diagnostic products.

Collaborated with

Chinese Medical

Association

June 2016

June 2016

Singlera Genomics Shanghai collaborated with the Pathology Branch of the Chinese Medical Association to initiate the first multi-center study of molecular pathology in China.

MANAGEMENT TEAM

  • Led by Yuan Gao and Kun Zhang, Singlera Genomics Inc. was founded in San Diego, California, US in July 2014.
  • Shanghai Singlera Genomics Inc. was founded in Shanghai, CN in early 2015.
  • Built on top the cutting-edge technologies developed by the two professors, we will develop in vitro diagnostic assays for cancer and genetic diseases, and provide clinical and research services.

Scientific Advisory Board

  • Prof. George Church

    Harvard Medical School,

    elected member of NAS

    , NAE, AAAS

  • Prof. Zhou Honghao

    Director of Institute of

    Pharmacology,Central South

    University; elected memberof

    Chinese Academy of Engineering

  • Prof. Liu Xiaole

    Professor, Department of

    Biostatistics, Harvard

    University;Thousand Talents

    Program, Professor of

    Tongji University

  • Prof. Zhang Kun

    Department of Bioengineering,

    University of California

    at San Diego

  • Prof. Jin Li

    Vice President of Fudan University;

    elected member of Chinese

    Academy of Science

  • Prof. Cheng Liang

    Professor of pathology at

    the Indiana University

    Medical School

  • Prof. Gao Yuan

    Department of Biomedical

    Engineering, Johns Hopkins

    University

Cooperative Partners

办公地:上海浦东新区芙蓉花路500弄20号

备案号:沪ICP备15039944号-1

工信部网站:http://www.beian.gov.cn

  • RUI LIU, Ph.D.

    CO-FOUNDER

    CHIEF TECHNOLOGY OFFICER

    Dr. Liu has extensive experience in DNA epigenetics and methylation and RNA sequencing.

    Along with Yi Zhang at Harvard University, Dr. Liu first demonstrated the association between DNA demethylation and meiosis arrest in primordial germ cells during early embryonic development with ultra-low input RNA sequencing and whole-genome bisulfite sequencing, resulting in articles published on Nature and Cell Research. Dr. Liu also developed large-scale single-cell RNA sequencing technology for the NIH Single Cell Analysis Program, during which she coordinated multiple laboratories at UCSD, the Scripps Research Institute and Illumina to systematically map single-neuron RNA expression in the human brain. Dr. Liu received a Ph.D. in Genetics from University of Pennsylvania, completed her post-doctoral training then worked as a Project Scientist in the Department of Bioengineering at University of California San Diego with Dr. Kun Zhang, and has a Bachelor’s degree in Clinical Medicine from Peking University.

  • QIANG LIU, M.B.A.

    CO-FOUNDER

    CHIEF OPERATING OFFICER

    Mr. Liu is experienced in the evaluation of and investment in the biological and pharmaceutical industries and capital operations. Mr. Liu previously worked at the investment banks JP Morgan, Bank of New York, and Canadian Imperial Bank of Commerce. Mr. Liu has also successfully helped multiple Chinese companies in the United States and Canada on initial public offerings. Mr. Liu received his MBA from York University, Master of Biological Engineering from University of New South Wales, and B.S. in Biochemistry from Jilin University.

  • JOHNY ZHANG, M.B.A.

    CO-FOUNDER

    CHIEF EXECUTIVE OFFICER

    Johny Zhang was previously the Vice President/General Manager for Greater China Thermo Fisher Scientific Healthcare, where he was awarded the annual global CEO award for outstanding performance. During his tenure at Gene Company, Ltd, Mr. Zhang introduced numerous molecular diagnostic technologies into China, including Dako IHC, Abbott FISH, Qiagen Nucleic Acid Detection, and Affymatrix Gene Chip. Mr. Zhang co-founded and was COO of www.ebiotrade.com, the first Chinese universal life science website of its kind. Mr. Zhang received his MBA and B.S. in Biochemistry from Fudan University.

  • KUN ZHANG, Ph.D.

    CO-FOUNDER

    SCIENTIFIC ADVISOR

    Dr. Kun Zhang is an expert in development of genome technologies. Dr. Zhang is recognized for multiple major research achievments, including single-cell whole genome sequencing (with George Church), large-scale targeted DNA methylation sequencing (with Dr. Yuan Gao), characterization of somatic genomic instability in human induced pluripotent stem cells, development of the Microwell Displacement Amplification System (MIDAS) for single-cell genome sequencing, single cell sequencing of the human brain, and the development of methylation haplotyping technology for non-invasive detection of ctDNA in cancer patients. Dr. Zhang was elected as the Fellow of the American Institute for Medical and Biological Engineering for his outstanding contributions to the field of genome editing and technology and epigenetics. Dr. Zhang is Professor in the Department of Bioengineering at the University of California San Diego, holds a Ph.D. in Human and Molecular Genetics from the University of Texas Houston, completed his post-doctoral training with George Church at Harvard Medical School, and has a B.S. in Biophysics from Fudan University.

  • YUAN GAO, Ph.D.

    CO-FOUNDER

    CHAIRMAN OF THE BOARD

    Dr. Yuan Gao is an innovator of translational technologies for next generation sequencing, non-invasive prenatal testing (NIPT), DNA methylation sequencing, and digital information storage in DNA. Dr. Gao is listed in a number of patent applications and has published over 50 research articles, including in the journals Science, Nature and PNAS. Dr. Gao co-developed the first NIPT to detect Down Syndrome from blood, recognized as one of the top ten major medical breakthroughs in 2008 by Time Magazine. In addition, Dr. Gao, along with George Church and Sriram Kosuri, developed a digital information archiving system in DNA based on large-scale DNA synthesis. Dr. Gao also participated in the Deep Blue research project at the IBM Research Institute. Dr. Gao was also a founder and President of Med Data Quest, Inc., a information technology company developing clinical natural language processing and machine learning tools to aid precision medicine, an Associate Professor in the Department of Biomedical Engineering at Johns Hopkins University, has a Ph.D. in Computer Science from the Memphis University, completed his post-doctoral training with George Church at Harvard University, and has a Bachelor of Bioscience from Beijing University.

  • Singlera Genomics signed a collaborative agreement with Fudan University for a Precision Medicine study.

    Taizhou Cohort aids the development and validation of cancer early detection techniques.


    Early cancer diagnosis can greatly improves the outcomes of cancer patients; however, the diagnostic tests need to be validated with large aand prospective cohorts

    Fudan University’s Taizhou Cohort was established by Professor Jin Li, and has become the largest and world's leading cohort with 200,000 participants from a single municipal district and a biorepository of nearly 1.2 million biological samples, as well as detailed follow-up records of the population.

    Using its proprietary methylation-based non-invasive assays, Singlera Genomics will collaborate with the Taizhou Institute of Fudan University to validate their diagnostic tests for early cancer screening .

  • Collaboration between Singlera Genomics and the Pathology Branch of the Chinese Medical Association.

    The first national multi-center tumor NGS technology validation program.


    Standardization is the key to improving precision medicine

    In June 2016, led by the Pathology Branch of the Chinese Medical Association and organized by the Pathology Laboratory of West China Hospital, China's first multi-center NGS research project was initiated in collaboration with Singlera Genomics.

    More than ten large, grade 3 hospitals joined the project, including West China Hospital, Peking Union Medical College Hospital, Peking University Third Hospital, the 401st Hospital of PLA, Tumour Hospital of Chinese Academy of Medical Sciences, Shanghai Tumor Hospital, Shanghai Zhongshan Hospital, Xijing Hospital, and the First Affiliated Hospital of Zhengzhou University.

    The multi-center project aims to promote the application of NGS technology in the field of tumor pathology with multi-center/cross-platform validation of the effectiveness and reliability of NGS methods, and also promote the establishment of standardized tumor NGS workflow and quality control standards.

  • Strategic cooperation between Singlera Genomics and Xiangya Medical Laboratory.

    Jointly launched tumour-specific high-throughput sequencing testing services.


    Xiangya Medical Laboratory was founded by Professor Zhou Honghao, a clinical pharmacology expert and advocate of individualized medical care, with support from the Central South University Xiangya School of Medicine, Institute of Clinical Pharmacology and National Key Laboratory.

    National Health and Family Planning Commission Pilot unit of individualized medical examination (certificated in September 2013).

    First group of High Throughput Gene Sequencing Technology Pilot Unit certificated by National Health and Family Planning Commission (certificated by December 2014).

    First group of Pilot Unit of Tumor Diagnosis and Treatment Project, High Throughput Sequencing, Gene Detection Technology and Clinical Application (certificated in April 2015).

    Based on the large clinical sample size and rigorous laboratory developed testing procedures, a clinical sample collection service was jointly launched by the two parties.

  • Strategic cooperation between Singlera Genomics and Genor Biopharma.

    Joint development of tumor immunotherapy and companion diagnostic tests.


    Emerging companion diagnostic test for tumour immunotherapy.

    Genor Biopharma, founded by famous Chinese American scientist Dr. Xinhua Zhou, is an innovation-driven biopharmaceutical company focused on research and development and industrialization of therapeutic monoclonal antibodies and Fc-fusion protein drugs.

    Over ten investigational products of Genor Biopharma, five Class II therapeutic biological products and two Class I therapeutic biological products entered clinical trials and entered the registration phase, among which anti-PD-1 monoclonal antibody (Jienuo monoclonal antibody injection) was approved for clinical trials in February 2016.

    New methods of immunotherapy and companion diagnostic tests developed jointly by two parties.

  • Strategic partnership between Singlera Genomics and Xiangya Medical Laboratory.

    Jointly launched tumor-specific high-throughput sequencing testing services.


    Shanghai Genechem Co.,Ltd is currently the largest supplier of genetic research services in China, which has established the largest RNAi lentivirus library in China and hundreds of genes playing significant key role in specific tumour development. By cooperating with more than 10 oncologic fields and with over 7000 clinicians, Genechem has established a complete gene therapy research and development platform.



    Singlera Genomics and Genechem signed a strategic partnership agreement for clinical and research services related to cancer precision medicine.

Singlera Genomics is committed to the application of next generation sequencing to diagnose genetic diseases and disorders. Singlera Genomics develops non-invasive precision medicine diagnostics using proprietary technologies in single cell sequencing, DNA methylation and bioinformatics. Singlera Genomics products address the continuing need for cancer diagnosis, personalized cancer treatment, prenatal diagnosis, and pre-implantation genetic screening. Additionally, Singlera Genomics provides customized next generation sequencing services for pharmaceutical companies and medical research institutions. The company has operation centers in the United States and China.